-$0.12 Earnings Per Share Expected for Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) This Quarter

Equities analysts predict that Tabula Rasa HealthCare, Inc. (NASDAQ:TRHCGet Rating) will announce earnings of ($0.12) per share for the current quarter, Zacks reports. Five analysts have issued estimates for Tabula Rasa HealthCare’s earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.17). Tabula Rasa HealthCare posted earnings of ($0.09) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.21) to $0.05. For the next year, analysts anticipate that the business will post earnings of $0.07 per share, with EPS estimates ranging from ($0.34) to $0.50. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHCGet Rating) last announced its quarterly earnings data on Thursday, February 24th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $85.69 million during the quarter, compared to analysts’ expectations of $85.19 million. Tabula Rasa HealthCare had a negative net margin of 23.86% and a negative return on equity of 61.87%. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.53) EPS.

A number of equities analysts recently weighed in on TRHC shares. StockNews.com raised shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research report on Saturday, April 2nd. Robert W. Baird lowered shares of Tabula Rasa HealthCare from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $24.00 to $11.00 in a report on Tuesday, February 1st. Benchmark reduced their price objective on shares of Tabula Rasa HealthCare from $30.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, March 2nd. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a report on Tuesday, March 1st. Finally, SVB Leerink reduced their price objective on shares of Tabula Rasa HealthCare from $23.00 to $11.00 and set a “market perform” rating on the stock in a report on Monday, February 28th. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Tabula Rasa HealthCare currently has a consensus rating of “Hold” and a consensus target price of $14.53.

In other news, COO Michael Greenhalgh sold 2,010 shares of Tabula Rasa HealthCare stock in a transaction dated Friday, January 14th. The shares were sold at an average price of $14.87, for a total value of $29,888.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Brian W. Adams sold 1,958 shares of Tabula Rasa HealthCare stock in a transaction dated Wednesday, January 12th. The shares were sold at an average price of $15.68, for a total transaction of $30,701.44. The disclosure for this sale can be found here. In the last ninety days, insiders bought 17,000 shares of company stock worth $97,110 and sold 9,990 shares worth $151,909. 10.20% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Masso Torrence Wealth Management Inc. acquired a new stake in shares of Tabula Rasa HealthCare in the 4th quarter worth approximately $39,000. Emerald Advisers LLC purchased a new position in Tabula Rasa HealthCare in the 4th quarter valued at approximately $72,000. Captrust Financial Advisors increased its stake in Tabula Rasa HealthCare by 3,136.9% in the 3rd quarter. Captrust Financial Advisors now owns 5,794 shares of the company’s stock valued at $152,000 after purchasing an additional 5,615 shares in the last quarter. Advisor Group Holdings Inc. increased its stake in Tabula Rasa HealthCare by 19.6% in the 3rd quarter. Advisor Group Holdings Inc. now owns 6,006 shares of the company’s stock valued at $158,000 after purchasing an additional 983 shares in the last quarter. Finally, Maryland State Retirement & Pension System purchased a new position in Tabula Rasa HealthCare in the 3rd quarter valued at approximately $262,000. Institutional investors own 88.29% of the company’s stock.

NASDAQ TRHC opened at $4.96 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.22 and a debt-to-equity ratio of 6.26. The firm has a market cap of $127.63 million, a PE ratio of -1.46 and a beta of 1.33. The business’s fifty day simple moving average is $6.49 and its 200-day simple moving average is $13.74. Tabula Rasa HealthCare has a 52 week low of $4.25 and a 52 week high of $53.38.

Tabula Rasa HealthCare Company Profile (Get Rating)

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems.

Featured Stories

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.